Generic placeholder image

Current Chinese Chemistry

Author(s): Ishan Panchal*, Animesh G. Devgirkar, Ashish D. Patel, Afzal Nagani and Chaitali Lad

DOI: 10.2174/2666001601666200121163605

Cite As
Molecular Modelling, Synthesis and Biological Evaluation of Novel Benzimidazole Derivatives for the Treatment of Breast Cancer

Page: [11 - 20] Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Background: The treatment of cancer requires scientific advancement. ATP-competitive mTOR inhibitors have been studied as potential antitumor agents.

Objective: A series of substituted benzimidazole compounds were designed, synthesized and characterized via introducing 2-chloroquinolin into 2nd position and most title compounds exhibited enhanced anticancer activities.

Methods: To study the anticancer mechanism, VIa-VIh was successfully docked by iGEMDOCK 2.0 which gives good affinity towards m-TOR/PI3K dual inhibitors. The anti-proliferative activities of these compounds were evaluated on MCF-7 and A549 cell line for Breast and lung cancer, respectively.

Results: 2-(2-chloroquinolin-3-yl)-1H-benzoimidazol-1-yl)(phenyl)methanone (VIa) exhibited significant anti-proliferative activity, especially against breast cancer (IC50 197 μM) for MCF7 cell line and (2-(2- chloroquinolin-3-yl)-1H-benzo[d]imidazol-1-yl)(4-nitrophenyl)methanone (VIc) was significantly active against lung cancer (IC50 89 μM) for A579 cell line.

Conclusion: VIa gives more activity on breast cancer and it gives IC50 197 μM for MCF7 cell line and (2- (2-chloroquinolin-3-yl)-1H-benzo[d]imidazol-1-yl) (4-nitrophenyl) methanone (VIc) lung cancer IC50 89 μM for A579 cell line.

Keywords: Benzimidazole derivatives, molecular modelling, biological evaluation breast cancer, anticancer, 2-chloroquinolin, MCF7 cell line.

Graphical Abstract

[1]
Panchal, I.I.; Badeliya, S.N.; Patel, R.; Patel, A.; Devaligar, A. In silico analysis and molecular docking studies of novel 4-amino-3- (isoquinolin-4-yl)-1H-pyrazolo[3,4-d] pyrimidine derivatives as dual PI3-K/mTOR inhibitors. Curr. Drug Discov. Technol., 2019, 16(3), 297-306.
[http://dx.doi.org/10.2174/1568009618666181102144934] [PMID: 30387396]
[2]
Mao, B.; Gao, S.; Weng, Y.; Zhang, L.; Zhang, L. Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors. Eur. J. Med. Chem., 2017, 129, 135-150.
[http://dx.doi.org/10.1016/j.ejmech.2017.02.015] [PMID: 28235701]
[3]
Miao, Z. Yufang, Deng.; Lifeng, Z.; Guoyi, Y.; Fangying, Wang.; Ye Tian; Lanxi, Z.; Hongxia, J.; Yuanwei, C. Design, synthesis, and biological evaluation of dimorpholine substituted thienopyrimidines as potential class I PI3K/mTOR dual inhibitors. J. Med. Chem., 2017, 60, 4023-4035.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00357]
[4]
Ishan, I.P.; Roshani, R.; Ashish, D.P. Design, synthesis and pharmacological evalution of 1,3,4-Oxadiazole derivatives as collapsin response mediator protein 1 (CRMP 1) inhibitors. Curr. Drug Discov. Technol., 2019, 16, 1-11.
[5]
Lee, J.J.; Loh, K.; Yap, Y.S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol. Med., 2015, 12(4), 342-354.
[PMID: 26779371]
[6]
Wise-Draper, T.M.; Moorthy, G.; Salkeni, M.A.; Karim, N.A.; Thomas, H.E.; Mercer, C.A.; Beg, M.S.; O’Gara, S.; Olowokure, O.; Fathallah, H.; Kozma, S.C.; Thomas, G.; Rixe, O.; Desai, P.; Morris, J.C.A.S.; Nagla, A.K.; Hala, E.T.; Carol, A.M. M, Shalaan. A phase Ib study of the dual PI3K/mTOR inhibitor Dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies. Target. Oncol., 2017, 12(3), 323-332.
[http://dx.doi.org/10.1007/s11523-017-0482-9] [PMID: 28357727]
[7]
Fei, S.; Jinying, Z.; Hongyu, L.; Liangliang, Wu.; Hongyu, J.; Qiyan, Wu. The dual PI3K/mTOR inhibitor dactolisib elicits antitumor activity in vitro and in vivo. Oncotarget, 2018, 2, 9(1), 706-717.
[8]
Moore, K.N.; Bauer, T.M.; Falchook, G.S.; Chowdhury, S.; Patel, C.; Neuwirth, R.; Enke, A.; Zohren, F.; Patel, M.R. Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ESMO Open, 2018, 3(2)e000291
[http://dx.doi.org/10.1136/esmoopen-2017-000291] [PMID: 29464110]
[9]
Jiang, S.J.; Wang, S. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo. Tumour Biol., 2015, 36(10), 8177-8184.
[http://dx.doi.org/10.1007/s13277-015-3536-6] [PMID: 25990456]
[10]
Yang, H.; Rudge, D.G.; Koos, J.D.; Vaidialingam, B.; Yang, H.J.; Pavletich, N.P. mTOR kinase structure, mechanism and regulation. Nature, 2013, 497(7448), 217-223.
[http://dx.doi.org/10.1038/nature12122] [PMID: 23636326]
[11]
Ishan, P.; Ashish, S.; Animesh, D.; Umang, S.; Ashish, P.; Alkesh, P.; Dhrubo, J.S. In silico analysis and molecular docking studies of novel 6,7-dihydropyrano [2,3-d] pyrimidin-5-one derivatives as human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) Inhibitors. Curr. Cancer Ther. Rev., 2019, 15, 1-13.
[12]
Tekale, A.S.; Shaikh, S.A.L. Synthesis and characterisation of substituted quinoline by Vilsmeier-Haack reagent. Int. J. Chem. Stu., 2017, 5(1), 01-04.